{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:30:05Z","timestamp":1790713805314,"version":"4.1.0"},"reference-count":297,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013011","name":"Birzeit University","doi-asserted-by":"publisher","award":["240193"],"award-info":[{"award-number":["240193"]}],"id":[{"id":"10.13039\/100013011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013011","name":"Birzeit University","doi-asserted-by":"publisher","award":["241104"],"award-info":[{"award-number":["241104"]}],"id":[{"id":"10.13039\/100013011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Johann Ludwig Wilhelm Thudicum described sphingolipids (SLs) in the late nineteenth century, but it was only in the past fifty years that SL research surged in importance and applicability. Currently, sphingolipids and their metabolism are hotly debated topics in various biochemical fields. Similar to other macromolecular reactions, SL metabolism has important implications in health and disease in most cells. A plethora of SL-related genetic ailments has been described. Defects in SL catabolism can cause the accumulation of SLs, leading to many types of lysosomal storage diseases (LSDs) collectively called sphingolipidoses. These diseases mainly impact the neuronal and immune systems, but other systems can be affected as well. This review aims to present a comprehensive, up-to-date picture of the rapidly growing field of sphingolipid LSDs, their etiology, pathology, and potential therapeutic strategies. We first describe LSDs biochemically and briefly discuss their catabolism, followed by general aspects of the major diseases such as Gaucher, Krabbe, Fabry, and Farber among others. We conclude with an overview of the available and potential future therapies for many of the diseases. We strive to present the most important and recent findings from basic research and clinical applications, and to provide a valuable source for understanding these disorders.<\/jats:p>","DOI":"10.1186\/s12944-021-01466-0","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T09:20:03Z","timestamp":1620033603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Sphingolipid lysosomal storage diseases: from bench to bedside"],"prefix":"10.1186","volume":"20","author":[{"given":"Muna","family":"Abed Rabbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Khodour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie S.","family":"Kaguni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-9976","authenticated-orcid":false,"given":"Johnny","family":"Stiban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.febslet.2009.10.021","volume":"584","author":"T Kolter","year":"2010","unstructured":"Kolter T, Sandhoff K. Lysosomal degradation of membrane lipids. FEBS Lett. 2010;584:1700\u201312.","journal-title":"FEBS Lett"},{"key":"1466_CR2","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1007\/s00018-007-7076-0","volume":"64","author":"S Lahiri","year":"2007","unstructured":"Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci. 2007;64:2270\u201384.","journal-title":"Cell Mol Life Sci"},{"key":"1466_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.sjbs.2015.03.005","volume":"22","author":"M Abou-Ghali","year":"2015","unstructured":"Abou-Ghali M, Stiban J. Regulation of ceramide channel formation and disassembly: Insights on the initiation of apoptosis. Saudi J Biol Sci. 2015;22:760\u201372.","journal-title":"Saudi J Biol Sci"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-030-21735-8_15","volume":"1161","author":"S Albeituni","year":"2019","unstructured":"Albeituni S, Stiban J. Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation. Adv Exp Med Biol. 2019;1161:169\u201391.","journal-title":"Adv Exp Med Biol"},{"key":"1466_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/B978-0-444-63438-2.00010-9","volume-title":"Biochemistry of Lipids, Lipoproteins and Membranes 6th Edition","author":"A Futerman","year":"2016","unstructured":"Futerman A. Sphingolipids. In: Biochemistry of Lipids, Lipoproteins and Membranes 6th Edition; 2016. p. 297\u2013326."},{"key":"1466_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature13476","volume":"510","author":"FM Platt","year":"2014","unstructured":"Platt FM. Sphingolipid lysosomal storage disorders. Nature. 2014;510:68\u201375.","journal-title":"Nature"},{"key":"1466_CR7","first-page":"299","volume-title":"Lipids II: Phospholipids, Glycosphingolipids, and Cholesterol. Essentials of Medical Biochemistry 2nd Edition","author":"NV Bhagavan","year":"2015","unstructured":"Bhagavan NV, EunHa C. Lipids II: Phospholipids, Glycosphingolipids, and Cholesterol. Essentials of Medical Biochemistry 2nd Edition; 2015. p. 299\u2013320."},{"key":"1466_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/B978-044453219-0.50015-5","volume-title":"Biochemistry of Lipids, Lipoproteins and Membranes 5th Edition","author":"AH Merrill Jr","year":"2008","unstructured":"Merrill AH Jr. Sphingolipids. In: Biochemistry of Lipids, Lipoproteins and Membranes 5th Edition; 2008. p. 363\u201397."},{"key":"1466_CR9","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","volume":"33","author":"K Sandhoff","year":"2013","unstructured":"Sandhoff K, Harzer K. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J Neurosci. 2013;33:10195\u2013208.","journal-title":"J Neurosci"},{"key":"1466_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10545-014-9736-1","volume":"38","author":"L Astudillo","year":"2015","unstructured":"Astudillo L, Sabourdy F, Therville N, Bode H, Segui B, Andrieu-Abadie N, et al. Human genetic disorders of sphingolipid biosynthesis. J Inherit Metab Dis. 2015;38:65\u201376.","journal-title":"J Inherit Metab Dis"},{"key":"1466_CR11","doi-asserted-by":"crossref","unstructured":"Schulze H, Sandhoff K. Lysosomal lipid storage diseases. Cold Spring Harb Perspect Biol. 2011;3.","DOI":"10.1101\/cshperspect.a004804"},{"key":"1466_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","volume":"1793","author":"A Ballabio","year":"2009","unstructured":"Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta. 2009;1793:684\u201396.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/14084","volume":"1","author":"V Puri","year":"1999","unstructured":"Puri V, Watanabe R, Dominguez M, Sun X, Wheatley CL, Marks DL, et al. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol. 1999;1:386\u20138.","journal-title":"Nat Cell Biol"},{"key":"1466_CR14","unstructured":"Fuller, M., Meikle, P. J., and Hopwood, J. J. (2006) Epidemiology of lysosomal storage diseases: an overview. in Fabry Disease: Perspectives from 5 Years of FOS (Mehta, A., Beck, M., and Sunder-Plassmann, G. eds.), Oxford. pp"},{"key":"1466_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pcl.2017.11.011","volume":"65","author":"CM Bellettato","year":"2018","unstructured":"Bellettato CM, Hubert L, Scarpa M, Wangler MF. Inborn Errors of Metabolism Involving Complex Molecules: Lysosomal and Peroxisomal Storage Diseases. Pediatr Clin North Am. 2018;65:353\u201373.","journal-title":"Pediatr Clin North Am"},{"key":"1466_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1542\/peds.2008-0635","volume":"123","author":"O Staretz-Chacham","year":"2009","unstructured":"Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics. 2009;123:1191\u2013207.","journal-title":"Pediatrics"},{"key":"1466_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jbior.2018.09.013","volume":"70","author":"G Wang","year":"2018","unstructured":"Wang G, Bieberich E. Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul. 2018;70:51\u201364.","journal-title":"Adv Biol Regul"},{"key":"1466_CR18","doi-asserted-by":"crossref","unstructured":"Santos R, Amaral O. Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20235897"},{"key":"1466_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ajcp\/55.2.237","volume":"55","author":"RN Hadley","year":"1971","unstructured":"Hadley RN, Hagstrom JW. Cardiac lesions in a patient with familial neurovisceral lipidosis (generalized gangliosidosis). Am J Clin Pathol. 1971;55:237\u201340.","journal-title":"Am J Clin Pathol"},{"key":"1466_CR20","first-page":"15","volume":"34","author":"E Gilbert-Barness","year":"2004","unstructured":"Gilbert-Barness E. Review: Metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci. 2004;34:15\u201334.","journal-title":"Ann Clin Lab Sci"},{"key":"1466_CR21","first-page":"659","volume-title":"The Sphingolipidoses. in Health Care for People with Intellectual and Developmental Disabilities across the Lifespan (Rubin, I. L., Merrick, J., Greydanus, D. E., and Patel, D. R. eds.)","author":"R Conway","year":"2016","unstructured":"Conway R. The Sphingolipidoses. in Health Care for People with Intellectual and Developmental Disabilities across the Lifespan (Rubin, I. L., Merrick, J., Greydanus, D. E., and Patel, D. R. eds.). Cham: Springer International Publishing; 2016. p. 659\u201382."},{"key":"1466_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","volume":"688","author":"CR Gault","year":"2010","unstructured":"Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1\u201323.","journal-title":"Adv Exp Med Biol"},{"key":"1466_CR23","doi-asserted-by":"publisher","first-page":"178910","DOI":"10.1155\/2013\/178910","volume":"2013","author":"R Pralhada Rao","year":"2013","unstructured":"Pralhada Rao R, Vaidyanathan N, Rengasamy M, Mammen Oommen A, Somaiya N, Jagannath MR. Sphingolipid metabolic pathway: an overview of major roles played in human diseases. J Lipids. 2013;2013:178910.","journal-title":"J Lipids"},{"key":"1466_CR24","doi-asserted-by":"publisher","first-page":"105014","DOI":"10.1016\/j.nbd.2020.105014","volume":"143","author":"DC Pant","year":"2020","unstructured":"Pant DC, Aguilera-Albesa S, Pujol A. Ceramide signalling in inherited and multifactorial brain metabolic diseases. Neurobiol Dis. 2020;143:105014.","journal-title":"Neurobiol Dis"},{"key":"1466_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41598-018-37946-0","volume":"9","author":"KH Park","year":"2019","unstructured":"Park KH, Ye ZW, Zhang J, Hammad SM, Townsend DM, Rockey DC, et al. 3-ketodihydrosphingosine reductase mutation induces steatosis and hepatic injury in zebrafish. Sci Rep. 2019;9:1138.","journal-title":"Sci Rep"},{"key":"1466_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.tcb.2012.04.005","volume":"22","author":"O Florey","year":"2012","unstructured":"Florey O, Overholtzer M. Autophagy proteins in macroendocytic engulfment. Trends Cell Biol. 2012;22:374\u201380.","journal-title":"Trends Cell Biol"},{"key":"1466_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.cellbio.21.122303.120013","volume":"21","author":"T Kolter","year":"2005","unstructured":"Kolter T, Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol. 2005;21:81\u2013103.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1466_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nature08849","volume":"464","author":"T Wollert","year":"2010","unstructured":"Wollert T, Hurley JH. Molecular mechanism of multivesicular body biogenesis by ESCRT complexes. Nature. 2010;464:864\u20139.","journal-title":"Nature"},{"key":"1466_CR29","doi-asserted-by":"crossref","unstructured":"Matsuda J. Sphingolipid Activator Proteins.\u00a0Tokyo: Springer Experimental Glycoscience; 2008. p. 125\u20139.","DOI":"10.1007\/978-4-431-77922-3_31"},{"key":"1466_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF00219682","volume":"92","author":"V Bradova","year":"1993","unstructured":"Bradova V, Smid F, Ulrich-Bott B, Roggendorf W, Paton BC, Harzer K. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum Genet. 1993;92:143\u201352.","journal-title":"Hum Genet"},{"key":"1466_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1096\/fasebj.5.3.2001789","volume":"5","author":"JS O'Brien","year":"1991","unstructured":"O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J. 1991;5:301\u20138.","journal-title":"FASEB J"},{"key":"1466_CR32","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0021-9258(19)39921-1","volume":"265","author":"S Morimoto","year":"1990","unstructured":"Morimoto S, Kishimoto Y, Tomich J, Weiler S, Ohashi T, Barranger JA, et al. Interaction of saposins, acidic lipids, and glucosylceramidase. J Biol Chem. 1990;265:1933\u20137.","journal-title":"J Biol Chem"},{"key":"1466_CR33","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1073\/pnas.86.9.3389","volume":"86","author":"S Morimoto","year":"1989","unstructured":"Morimoto S, Martin BM, Yamamoto Y, Kretz KA, O'Brien JS, Kishimoto Y. Saposin A: second cerebrosidase activator protein. Proc Natl Acad Sci U S A. 1989;86:3389\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0006-291X(88)80855-6","volume":"156","author":"S Morimoto","year":"1988","unstructured":"Morimoto S, Martin BM, Kishimoto Y, O'Brien JS. Saposin D: a sphingomyelinase activator. Biochem Biophys Res Commun. 1988;156:403\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"1466_CR35","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1194\/jlr.M300037-JLR200","volume":"44","author":"RD Duan","year":"2003","unstructured":"Duan RD, Cheng Y, Hansen G, Hertervig E, Liu JJ, Syk I, et al. Purification, localization, and expression of human intestinal alkaline sphingomyelinase. J Lipid Res. 2003;44:1241\u201350.","journal-title":"J Lipid Res"},{"key":"1466_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jbior.2014.10.002","volume":"57","author":"AA Shamseddine","year":"2015","unstructured":"Shamseddine AA, Airola MV, Hannun YA. Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv Biol Regul. 2015;57:24\u201341.","journal-title":"Adv Biol Regul"},{"key":"1466_CR37","doi-asserted-by":"publisher","first-page":"18431","DOI":"10.1074\/jbc.271.31.18431","volume":"271","author":"SL Schissel","year":"1996","unstructured":"Schissel SL, Schuchman EH, Williams KJ, Tabas I. Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem. 1996;271:18431\u20136.","journal-title":"J Biol Chem"},{"key":"1466_CR38","doi-asserted-by":"publisher","first-page":"7324","DOI":"10.1074\/jbc.M508382200","volume":"281","author":"M Kono","year":"2006","unstructured":"Kono M, Dreier JL, Ellis JM, Allende ML, Kalkofen DN, Sanders KM, et al. Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids. J Biol Chem. 2006;281:7324\u201331.","journal-title":"J Biol Chem"},{"key":"1466_CR39","doi-asserted-by":"publisher","first-page":"36592","DOI":"10.1074\/jbc.M506827200","volume":"280","author":"M Tani","year":"2005","unstructured":"Tani M, Igarashi Y, Ito M. Involvement of neutral ceramidase in ceramide metabolism at the plasma membrane and in extracellular milieu. J Biol Chem. 2005;280:36592\u2013600.","journal-title":"J Biol Chem"},{"key":"1466_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_217","volume":"259","author":"M Maceyka","year":"2020","unstructured":"Maceyka M, Rohrbach T, Milstien S, Spiegel S. Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma. Handb Exp Pharmacol. 2020;259:3\u201317.","journal-title":"Handb Exp Pharmacol"},{"key":"1466_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10409238.2017.1337706","volume":"52","author":"T Rohrbach","year":"2017","unstructured":"Rohrbach T, Maceyka M, Spiegel S. Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology. Crit Rev Biochem Mol Biol. 2017;52:543\u201353.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"1466_CR42","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1074\/jbc.M116.762377","volume":"292","author":"S Lima","year":"2017","unstructured":"Lima S, Milstien S, Spiegel S. Sphingosine and Sphingosine Kinase 1 Involvement in Endocytic Membrane Trafficking. J Biol Chem. 2017;292:3074\u201388.","journal-title":"J Biol Chem"},{"key":"1466_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50\u201360.","journal-title":"Trends Cell Biol"},{"key":"1466_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.prostaglandins.2012.08.003","volume":"99","author":"AJ Snider","year":"2012","unstructured":"Snider AJ, Wu BX, Jenkins RW, Sticca JA, Kawamori T, Hannun YA, et al. Loss of neutral ceramidase increases inflammation in a mouse model of inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2012;99:124\u201330.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1466_CR45","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1096\/fj.201700445RR","volume":"32","author":"F Li","year":"2018","unstructured":"Li F, Xu R, Low BE, Lin CL, Garcia-Barros M, Schrandt J, et al. Alkaline ceramidase 2 is essential for the homeostasis of plasma sphingoid bases and their phosphates. FASEB J. 2018;32:3058\u201369.","journal-title":"FASEB J"},{"key":"1466_CR46","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.bbamem.2006.05.027","volume":"1758","author":"T Kolter","year":"2006","unstructured":"Kolter T, Sandhoff K. Sphingolipid metabolism diseases. Biochim Biophys Acta. 2006;1758:2057\u201379.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/oxfordjournals.jbchem.a022101","volume":"124","author":"K Suzuki","year":"1998","unstructured":"Suzuki K, Vanier MT. Induced mouse models of abnormal sphingolipid metabolism. J Biochem. 1998;124:8\u201319.","journal-title":"J Biochem"},{"key":"1466_CR48","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1007\/s11064-012-0744-y","volume":"37","author":"RK Yu","year":"2012","unstructured":"Yu RK, Tsai YT, Ariga T. Functional roles of gangliosides in neurodevelopment: an overview of recent advances. Neurochem Res. 2012;37:1230\u201344.","journal-title":"Neurochem Res"},{"key":"1466_CR49","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ana.410310316","volume":"31","author":"K Yoshida","year":"1992","unstructured":"Yoshida K, Oshima A, Sakuraba H, Nakano T, Yanagisawa N, Inui K, et al. GM1 gangliosidosis in adults: clinical and molecular analysis of 16 Japanese patients. Ann Neurol. 1992;31:328\u201332.","journal-title":"Ann Neurol"},{"key":"1466_CR50","unstructured":"Regier DS, Tifft CJ. GLB1-Related Disorders. in GeneReviews((R)) Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. eds. Seattle: 1993."},{"key":"1466_CR51","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/B978-0-444-59565-2.00039-3","volume":"113","author":"MC Patterson","year":"2013","unstructured":"Patterson MC. Gangliosidoses. Handb Clin Neurol. 2013;113:1707\u20138.","journal-title":"Handb Clin Neurol"},{"key":"1466_CR52","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.20593","volume":"20","author":"E Roze","year":"2005","unstructured":"Roze E, Paschke E, Lopez N, Eck T, Yoshida K, Maurel-Ollivier A, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord. 2005;20:1366\u20139.","journal-title":"Mov Disord"},{"key":"1466_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ymgme.2009.01.003","volume":"97","author":"AM Bradbury","year":"2009","unstructured":"Bradbury AM, Morrison NE, Hwang M, Cox NR, Baker HJ, Martin DR. Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency. Mol Genet Metab. 2009;97:53\u20139.","journal-title":"Mol Genet Metab"},{"key":"1466_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029074","volume":"6","author":"T Kodama","year":"2011","unstructured":"Kodama T, Togawa T, Tsukimura T, Kawashima I, Matsuoka K, Kitakaze K, et al. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease. PLoS One. 2011;6:e29074.","journal-title":"PLoS One"},{"key":"1466_CR55","doi-asserted-by":"crossref","unstructured":"Hadipour, Z., Shafeghati, Y., Tonekaboni, H., Verheijen, F. W., Rolfs, A., and Hadipour, F. (2018) Tay-Sachs Disease; Report of 6 Iranian Patients and Review of Literature. 2","DOI":"10.29252\/sjrm.2.1.35"},{"key":"1466_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mgene.2014.01.007","volume":"2","author":"T Georgiou","year":"2014","unstructured":"Georgiou T, Christopoulos G, Anastasiadou V, Hadjiloizou S, Cregeen D, Jackson M, et al. The first family with Tay-Sachs disease in Cyprus: Genetic analysis reveals a nonsense (c.78G>A) and a silent (c.1305C>T) mutation and allows preimplantation genetic diagnosis. Meta Gene. 2014;2:200\u20135.","journal-title":"Meta Gene"},{"key":"1466_CR57","unstructured":"Kaback MM, Desnick RJ. Hexosaminidase A Deficiency. in GeneReviews((R)) Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A eds. Seattle: 1993."},{"key":"1466_CR58","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1111\/j.1471-4159.1971.tb00204.x","volume":"18","author":"K Sandhoff","year":"1971","unstructured":"Sandhoff K, Harzer K, Wassle W, Jatzkewitz H. Enzyme alterations and lipid storage in three variants of Tay-Sachs disease. J Neurochem. 1971;18:2469\u201389.","journal-title":"J Neurochem"},{"key":"1466_CR59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-018-0876-5","volume":"13","author":"AR Tavasoli","year":"2018","unstructured":"Tavasoli AR, Parvaneh N, Ashrafi MR, Rezaei Z, Zschocke J, Rostami P. Clinical presentation and outcome in infantile Sandhoff disease: a case series of 25 patients from Iranian neurometabolic bioregistry with five novel mutations. Orphanet J Rare Dis. 2018;13:130.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR60","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1073\/pnas.75.8.3979","volume":"75","author":"E Conzelmann","year":"1978","unstructured":"Conzelmann E, Sandhoff K. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci U S A. 1978;75:3979\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1086\/302463","volume":"65","author":"B Chen","year":"1999","unstructured":"Chen B, Rigat B, Curry C, Mahuran DJ. Structure of the GM2A gene: identification of an exon 2 nonsense mutation and a naturally occurring transcript with an in-frame deletion of exon 2. Am J Hum Genet. 1999;65:77\u201387.","journal-title":"Am J Hum Genet"},{"key":"1466_CR62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0925-4439(99)00074-5","volume":"1455","author":"DJ Mahuran","year":"1999","unstructured":"Mahuran DJ. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta. 1999;1455:105\u201338.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR63","first-page":"1048","volume":"59","author":"U Schepers","year":"1996","unstructured":"Schepers U, Glombitza G, Lemm T, Hoffmann A, Chabas A, Ozand P, et al. Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant. Am J Hum Genet. 1996;59:1048\u201356.","journal-title":"Am J Hum Genet"},{"key":"1466_CR64","doi-asserted-by":"crossref","unstructured":"Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015:CD010324.","DOI":"10.1002\/14651858.CD010324.pub2"},{"key":"1466_CR65","doi-asserted-by":"crossref","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18.","DOI":"10.3390\/ijms18020441"},{"key":"1466_CR66","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118\u201327.","journal-title":"Blood"},{"key":"1466_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2013.02.024","volume":"1508","author":"JS Won","year":"2013","unstructured":"Won JS, Kim J, Paintlia MK, Singh I, Singh AK. Role of endogenous psychosine accumulation in oligodendrocyte differentiation and survival: implication for Krabbe disease. Brain Res. 2013;1508:44\u201352.","journal-title":"Brain Res"},{"key":"1466_CR68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","volume":"4","author":"A Nagral","year":"2014","unstructured":"Nagral A. Gaucher disease. J Clin Exp Hepatol. 2014;4:37\u201350.","journal-title":"J Clin Exp Hepatol"},{"key":"1466_CR69","unstructured":"Pastores, G. M., and Hughes, D. A. (1993) Gaucher Disease. in GeneReviews((R)) (Adam, M. P., Ardinger, H. H., Pagon, R. A., Wallace, S. E., Bean, L. J. H., Stephens, K., and Amemiya, A. eds.), Seattle (WA). pp"},{"key":"1466_CR70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160:603\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1466_CR71","first-page":"158","volume":"2","author":"R Kauli","year":"2000","unstructured":"Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy. Isr Med Assoc J. 2000;2:158\u201363.","journal-title":"Isr Med Assoc J"},{"key":"1466_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Mol Genet Metab. 2017;120:27\u201333.","journal-title":"Mol Genet Metab"},{"key":"1466_CR73","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66:228\u201332.","journal-title":"Neurology"},{"key":"1466_CR74","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","volume":"118","author":"D Cassiman","year":"2016","unstructured":"Cassiman D, Packman S, Bembi B, Turkia HB, Al-Sayed M, Schiff M, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases. Mol Genet Metab. 2016;118:206\u201313.","journal-title":"Mol Genet Metab"},{"key":"1466_CR75","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/A:1022501702403","volume":"24","author":"C Rodriguez-Lafrasse","year":"1999","unstructured":"Rodriguez-Lafrasse C, Vanier MT. Sphingosylphosphorylcholine in Niemann-Pick disease brain: accumulation in type A but not in type B. Neurochem Res. 1999;24:199\u2013205.","journal-title":"Neurochem Res"},{"key":"1466_CR76","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","volume":"107","author":"CE Hollak","year":"2012","unstructured":"Hollak CE, de Sonnaville ES, Cassiman D, Linthorst GE, Groener JE, Morava E, et al. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab. 2012;107:526\u201333.","journal-title":"Mol Genet Metab"},{"key":"1466_CR77","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013;15:618\u201323.","journal-title":"Genet Med"},{"key":"1466_CR78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13023-018-0845-z","volume":"13","author":"FPS Yu","year":"2018","unstructured":"Yu FPS, Amintas S, Levade T, Medin JA. Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet J Rare Dis. 2018;13:121.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR79","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1651-2227.1958.tb07665.x","volume":"47","author":"R Zetterstrom","year":"1958","unstructured":"Zetterstrom R. Disseminated lipogranulomatosis (Farber's disease). Acta Paediatr. 1958;47:501\u201310.","journal-title":"Acta Paediatr"},{"key":"1466_CR80","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2350\/07-08-0318.1","volume":"11","author":"A Willis","year":"2008","unstructured":"Willis A, Vanhuse C, Newton KP, Wasserstein M, Morotti RA. Farber's disease type IV presenting with cholestasis and neonatal liver failure: report of two cases. Pediatr Dev Pathol. 2008;11:305\u20138.","journal-title":"Pediatr Dev Pathol"},{"key":"1466_CR81","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF00441558","volume":"148","author":"C Fusch","year":"1989","unstructured":"Fusch C, Huenges R, Moser HW, Sewell AC, Roggendorf W, Kustermann-Kuhn B, et al. A case of combined Farber and Sandhoff disease. Eur J Pediatr. 1989;148:558\u201362.","journal-title":"Eur J Pediatr"},{"key":"1466_CR82","first-page":"77","volume":"113","author":"AV Chaves-Markman","year":"2019","unstructured":"Chaves-Markman AV, Markman M, Calado EB, Pires RF, Santos-Veloso MAO, Pereira CMF, et al. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease? Arq Bras Cardiol. 2019;113:77\u201384.","journal-title":"Arq Bras Cardiol"},{"key":"1466_CR83","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR84","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","volume":"28","author":"TR Hsu","year":"2018","unstructured":"Hsu TR, Niu DM. Fabry disease: Review and experience during newborn screening. Trends Cardiovasc Med. 2018;28:274\u201381.","journal-title":"Trends Cardiovasc Med"},{"key":"1466_CR85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR86","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006;43:347\u201352.","journal-title":"J Med Genet"},{"key":"1466_CR87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet"},{"key":"1466_CR88","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/jhg.2010.58","volume":"55","author":"BH Lee","year":"2010","unstructured":"Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010;55:512\u20137.","journal-title":"J Hum Genet"},{"key":"1466_CR89","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jbspin.2003.10.015","volume":"71","author":"C Masson","year":"2004","unstructured":"Masson C, Cisse I, Simon V, Insalaco P, Audran M. Fabry disease: a review. Joint Bone Spine. 2004;71:381\u20133.","journal-title":"Joint Bone Spine"},{"issue":"Suppl 1","key":"1466_CR90","first-page":"689","volume":"13","author":"ER Bongarzone","year":"2016","unstructured":"Bongarzone ER, Escolar ML, Gray SJ, Kafri T, Vite CH, Sands MS. Insights into the Pathogenesis and Treatment of Krabbe Disease. Pediatr Endocrinol Rev. 2016;13(Suppl 1):689\u201396.","journal-title":"Pediatr Endocrinol Rev"},{"key":"1466_CR91","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/hmg\/10.11.1191","volume":"10","author":"J Matsuda","year":"2001","unstructured":"Matsuda J, Vanier MT, Saito Y, Tohyama J, Suzuki K, Suzuki K. A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum Mol Genet. 2001;10:1191\u20139.","journal-title":"Hum Mol Genet"},{"key":"1466_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/mgme.2000.2990","volume":"70","author":"DA Wenger","year":"2000","unstructured":"Wenger DA, Rafi MA, Luzi P, Datto J, Costantino-Ceccarini E. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab. 2000;70:1\u20139.","journal-title":"Mol Genet Metab"},{"key":"1466_CR93","doi-asserted-by":"publisher","first-page":"280","DOI":"10.5582\/irdr.2016.01085","volume":"5","author":"A Ozkan","year":"2016","unstructured":"Ozkan A, Ozkara HA. Metachromatic leukodystrophy: Biochemical characterization of two (p.307Glu-->Lys, p.318Trp-->Cys) arylsulfatase A mutations. Intractable Rare Dis Res. 2016;5:280\u20133.","journal-title":"Intractable Rare Dis Res"},{"key":"1466_CR94","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","volume":"73","author":"S Groeschel","year":"2016","unstructured":"Groeschel S, Kuhl JS, Bley AE, Kehrer C, Weschke B, Doring M, et al. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients. JAMA Neurol. 2016;73:1133\u201340.","journal-title":"JAMA Neurol"},{"key":"1466_CR95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1172-9-18","volume":"9","author":"C Kehrer","year":"2014","unstructured":"Kehrer C, Groeschel S, Kustermann-Kuhn B, Burger F, Kohler W, Kohlschutter A, et al. Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort. Orphanet J Rare Dis. 2014;9:18.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR96","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1600-0854.2010.01032.x","volume":"11","author":"E Lloyd-Evans","year":"2010","unstructured":"Lloyd-Evans E, Platt FM. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic. 2010;11:419\u201328.","journal-title":"Traffic"},{"key":"1466_CR97","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1091\/mbc.12.3.601","volume":"12","author":"DC Ko","year":"2001","unstructured":"Ko DC, Gordon MD, Jin JY, Scott MP. Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell. 2001;12:601\u201314.","journal-title":"Mol Biol Cell"},{"key":"1466_CR98","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1042\/BST20140311","volume":"43","author":"H Waller-Evans","year":"2015","unstructured":"Waller-Evans H, Lloyd-Evans E. Regulation of TRPML1 function. Biochem Soc Trans. 2015;43:442\u20136.","journal-title":"Biochem Soc Trans"},{"key":"1466_CR99","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1750-1172-8-166","volume":"8","author":"E Mengel","year":"2013","unstructured":"Mengel E, Klunemann HH, Lourenco CM, Hendriksz CJ, Sedel F, Walterfang M, et al. Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis. 2013;8:166.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR100","doi-asserted-by":"crossref","unstructured":"Khan A, Sergi C. Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder. Diagnostics (Basel). 2018;8.","DOI":"10.3390\/diagnostics8020029"},{"key":"1466_CR101","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.bbadis.2011.03.018","volume":"1812","author":"A Caciotti","year":"2011","unstructured":"Caciotti A, Garman SC, Rivera-Colon Y, Procopio E, Catarzi S, Ferri L, et al. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta. 2011;1812:782\u201390.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR102","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.ymgmr.2019.100513","volume":"21","author":"YL Latour","year":"2019","unstructured":"Latour YL, Yoon R, Thomas SE, Grant C, Li C, Sena-Esteves M, et al. Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis. Mol Genet Metab Rep. 2019;21:100513.","journal-title":"Mol Genet Metab Rep"},{"key":"1466_CR103","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tibs.2015.04.005","volume":"40","author":"RW Ledeen","year":"2015","unstructured":"Ledeen RW, Wu G. The multi-tasked life of GM1 ganglioside, a true factotum of nature. Trends Biochem Sci. 2015;40:407\u201318.","journal-title":"Trends Biochem Sci"},{"key":"1466_CR104","doi-asserted-by":"publisher","first-page":"15912","DOI":"10.1073\/pnas.2536657100","volume":"100","author":"J Matsuda","year":"2003","unstructured":"Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, Takimoto K, et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A. 2003;100:15912\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR105","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","volume":"46","author":"JL Kasperzyk","year":"2005","unstructured":"Kasperzyk JL, d'Azzo A, Platt FM, Alroy J, Seyfried TN. Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res. 2005;46:744\u201351.","journal-title":"J Lipid Res"},{"key":"1466_CR106","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1566523218666180404162622","volume":"18","author":"MB Cachon-Gonzalez","year":"2018","unstructured":"Cachon-Gonzalez MB, Zaccariotto E, Cox TM. Genetics and Therapies for GM2 Gangliosidosis. Curr Gene Ther. 2018;18:68\u201389.","journal-title":"Curr Gene Ther"},{"key":"1466_CR107","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1074\/jbc.M105457200","volume":"277","author":"ST Hepbildikler","year":"2002","unstructured":"Hepbildikler ST, Sandhoff R, Kolzer M, Proia RL, Sandhoff K. Physiological substrates for human lysosomal beta -hexosaminidase S. J Biol Chem. 2002;277:2562\u201372.","journal-title":"J Biol Chem"},{"key":"1466_CR108","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/j.1460-2075.1983.tb01567.x","volume":"2","author":"HJ Kytzia","year":"1983","unstructured":"Kytzia HJ, Hinrichs U, Maire I, Suzuki K, Sandhoff K. Variant of GM2-gangliosidosis with hexosaminidase A having a severely changed substrate specificity. EMBO J. 1983;2:1201\u20135.","journal-title":"EMBO J"},{"key":"1466_CR109","doi-asserted-by":"publisher","first-page":"21705","DOI":"10.1016\/S0021-9258(20)88243-X","volume":"264","author":"CA Brown","year":"1989","unstructured":"Brown CA, Neote K, Leung A, Gravel RA, Mahuran DJ. Introduction of the alpha subunit mutation associated with the B1 variant of Tay-Sachs disease into the beta subunit produces a beta-hexosaminidase B without catalytic activity. J Biol Chem. 1989;264:21705\u201310.","journal-title":"J Biol Chem"},{"key":"1466_CR110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","volume":"22","author":"L Nalysnyk","year":"2017","unstructured":"Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22:65\u201373.","journal-title":"Hematology"},{"key":"1466_CR111","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1038\/s41598-019-41914-7","volume":"9","author":"B Liou","year":"2019","unstructured":"Liou B, Zhang W, Fannin V, Quinn B, Ran H, Xu K, et al. Combination of acid beta-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype. Sci Rep. 2019;9:5571.","journal-title":"Sci Rep"},{"key":"1466_CR112","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10545-006-0411-z","volume":"29","author":"M Elleder","year":"2006","unstructured":"Elleder M. Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis. 2006;29:707\u201315.","journal-title":"J Inherit Metab Dis"},{"key":"1466_CR113","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1172\/JCI29224","volume":"116","author":"Y Yildiz","year":"2006","unstructured":"Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, et al. Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest. 2006;116:2985\u201394.","journal-title":"J Clin Invest"},{"key":"1466_CR114","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.1400768111","volume":"111","author":"PK Mistry","year":"2014","unstructured":"Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, et al. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A. 2014;111:4934\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR115","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine Promotes alpha-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease. J Neurosci. 2017;37:9617\u201331.","journal-title":"J Neurosci"},{"key":"1466_CR116","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/08830738030180090201","volume":"18","author":"K Suzuki","year":"2003","unstructured":"Suzuki K. Globoid cell leukodystrophy (Krabbe's disease): update. J Child Neurol. 2003;18:595\u2013603.","journal-title":"J Child Neurol"},{"key":"1466_CR117","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1083\/jcb.153.2.429","volume":"153","author":"DS Im","year":"2001","unstructured":"Im DS, Heise CE, Nguyen T, O'Dowd BF, Lynch KR. Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol. 2001;153:429\u201334.","journal-title":"J Cell Biol"},{"key":"1466_CR118","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1471-4159.1996.66031118.x","volume":"66","author":"N Sakai","year":"1996","unstructured":"Sakai N, Inui K, Tatsumi N, Fukushima H, Nishigaki T, Taniike M, et al. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J Neurochem. 1996;66:1118\u201324.","journal-title":"J Neurochem"},{"key":"1466_CR119","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/mgme.2001.3194","volume":"73","author":"P Luzi","year":"2001","unstructured":"Luzi P, Rafi MA, Zaka M, Curtis M, Vanier MT, Wenger DA. Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease). Mol Genet Metab. 2001;73:211\u201323.","journal-title":"Mol Genet Metab"},{"key":"1466_CR120","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"1466_CR121","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/8904_2012_165","volume":"8","author":"J Villalobos","year":"2013","unstructured":"Villalobos J, Politei JM, Martins AM, Cabrera G, Amartino H, Lemay R, et al. Fabry disease in latin america: data from the fabry registry. JIMD Rep. 2013;8:91\u20139.","journal-title":"JIMD Rep"},{"key":"1466_CR122","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Nino","year":"2011","unstructured":"Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26:1797\u2013802.","journal-title":"Nephrol Dial Transplant"},{"key":"1466_CR123","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013;9:e1003632.","journal-title":"PLoS Genet"},{"key":"1466_CR124","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","volume":"29","author":"SD Kingma","year":"2015","unstructured":"Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29:145\u201357.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1466_CR125","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1093\/hmg\/ddy155","volume":"27","author":"MT Fiorenza","year":"2018","unstructured":"Fiorenza MT, Moro E, Erickson RP. The pathogenesis of lysosomal storage disorders: beyond the engorgement of lysosomes to abnormal development and neuroinflammation. Hum Mol Genet. 2018;27:R119\u201329.","journal-title":"Hum Mol Genet"},{"key":"1466_CR126","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ceca.2011.03.010","volume":"50","author":"E Lloyd-Evans","year":"2011","unstructured":"Lloyd-Evans E, Platt FM. Lysosomal Ca (2+) homeostasis: role in pathogenesis of lysosomal storage diseases. Cell Calcium. 2011;50:200\u20135.","journal-title":"Cell Calcium"},{"key":"1466_CR127","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1074\/jbc.M109.037622","volume":"285","author":"SD Goldman","year":"2010","unstructured":"Goldman SD, Krise JP. Niemann-Pick C1 functions independently of Niemann-Pick C2 in the initial stage of retrograde transport of membrane-impermeable lysosomal cargo. J Biol Chem. 2010;285:4983\u201394.","journal-title":"J Biol Chem"},{"key":"1466_CR128","doi-asserted-by":"crossref","unstructured":"Simonaro CM. Lysosomes, Lysosomal Storage Diseases, and Inflammation. J Inborn Errors Metabol Screening. 2016.","DOI":"10.1177\/2326409816650465"},{"key":"1466_CR129","volume-title":"Handbook of Neurochemistry and Molecular Neurobiology (A., L., G., T., and G., G. eds.)","author":"SL Hoops","year":"2009","unstructured":"Hoops SL, Kolter T, Sandhoff K. Sphingolipid-Inherited Diseases of the Central Nervous System. In: Handbook of Neurochemistry and Molecular Neurobiology (A., L., G., T., and G., G. eds.). Boston, MA: Springer; 2009."},{"key":"1466_CR130","doi-asserted-by":"publisher","first-page":"e75720","DOI":"10.1371\/journal.pone.0075720","volume":"8","author":"K Vajn","year":"2013","unstructured":"Vajn K, Viljetic B, Degmecic IV, Schnaar RL, Heffer M. Differential distribution of major brain gangliosides in the adult mouse central nervous system. PLoS One. 2013;8:e75720.","journal-title":"PLoS One"},{"key":"1466_CR131","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0005-2760(73)90055-6","volume":"296","author":"G Tettamanti","year":"1973","unstructured":"Tettamanti G, Bonali F, Marchesini S, Zambotti V. A new procedure for the extraction, purification and fractionation of brain gangliosides. Biochim Biophys Acta. 1973;296:160\u201370.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR132","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","volume":"129","author":"M Jmoudiak","year":"2005","unstructured":"Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol. 2005;129:178\u201388.","journal-title":"Br J Haematol"},{"key":"1466_CR133","doi-asserted-by":"publisher","first-page":"F163","DOI":"10.1136\/fn.82.2.F163","volume":"82","author":"DL Stone","year":"2000","unstructured":"Stone DL, Carey WF, Christodoulou J, Sillence D, Nelson P, Callahan M, et al. Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed. 2000;82:F163\u20136.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1466_CR134","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1172\/JCI117160","volume":"93","author":"WM Holleran","year":"1994","unstructured":"Holleran WM, Ginns EI, Menon GK, Grundmann JU, Fartasch M, McKinney CE, et al. Consequences of beta-glucocerebrosidase deficiency in epidermis, Ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest. 1994;93:1756\u201364.","journal-title":"J Clin Invest"},{"key":"1466_CR135","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.expneurol.2016.04.002","volume":"283","author":"ID Duncan","year":"2016","unstructured":"Duncan ID, Radcliff AB. Inherited and acquired disorders of myelin: The underlying myelin pathology. Exp Neurol. 2016;283:452\u201375.","journal-title":"Exp Neurol"},{"key":"1466_CR136","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-4939-1154-7_12","volume":"9","author":"JM Boggs","year":"2014","unstructured":"Boggs JM. Role of galactosylceramide and sulfatide in oligodendrocytes and CNS myelin: formation of a glycosynapse. Adv Neurobiol. 2014;9:263\u201391.","journal-title":"Adv Neurobiol"},{"key":"1466_CR137","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF00209402","volume":"95","author":"S Kafert","year":"1995","unstructured":"Kafert S, Heinisch U, Zlotogora J, Gieselmann V. A missense mutation P136L in the arylsulfatase A gene causes instability and loss of activity of the mutant enzyme. Hum Genet. 1995;95:201\u20134.","journal-title":"Hum Genet"},{"key":"1466_CR138","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1172\/JCI115863","volume":"90","author":"B McInnes","year":"1992","unstructured":"McInnes B, Potier M, Wakamatsu N, Melancon SB, Klavins MH, Tsuji S, et al. An unusual splicing mutation in the HEXB gene is associated with dramatically different phenotypes in patients from different racial backgrounds. J Clin Invest. 1992;90:306\u201314.","journal-title":"J Clin Invest"},{"key":"1466_CR139","first-page":"900","volume":"35","author":"E Conzelmann","year":"1983","unstructured":"Conzelmann E, Kytzia HJ, Navon R, Sandhoff K. Ganglioside GM2 N-acetyl-beta-D-galactosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level. Am J Hum Genet. 1983;35:900\u201313.","journal-title":"Am J Hum Genet"},{"key":"1466_CR140","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/BF00219337","volume":"88","author":"P Leinekugel","year":"1992","unstructured":"Leinekugel P, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet. 1992;88:513\u201323.","journal-title":"Hum Genet"},{"key":"1466_CR141","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/08035320510028210","volume":"94","author":"V Gieselmann","year":"2005","unstructured":"Gieselmann V. What can cell biology tell us about heterogeneity in lysosomal storage diseases? Acta Paediatr Suppl. 2005;94:80\u20136 discussion 79.","journal-title":"Acta Paediatr Suppl"},{"key":"1466_CR142","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1023\/A:1005419122018","volume":"21","author":"T Kolter","year":"1998","unstructured":"Kolter T, Sandhoff K. Glycosphingolipid degradation and animal models of GM2-gangliosidoses. J Inherit Metab Dis. 1998;21:548\u201363.","journal-title":"J Inherit Metab Dis"},{"key":"1466_CR143","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nrg963","volume":"3","author":"RJ Desnick","year":"2002","unstructured":"Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet. 2002;3:954\u201366.","journal-title":"Nat Rev Genet"},{"key":"1466_CR144","doi-asserted-by":"publisher","first-page":"13280","DOI":"10.1073\/pnas.93.23.13280","volume":"93","author":"A Bosio","year":"1996","unstructured":"Bosio A, Binczek E, Stoffel W. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci U S A. 1996;93:13280\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR145","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-4684-7735-1_8","volume":"68","author":"M Vanier","year":"1976","unstructured":"Vanier M, Svennerholm L. Chemical pathology of Krabbe disease: the occurrence of psychosine and other neutral sphingoglycolipids. Adv Exp Med Biol. 1976;68:115\u201326.","journal-title":"Adv Exp Med Biol"},{"key":"1466_CR146","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0006-8993(96)00098-4","volume":"718","author":"H Yamada","year":"1996","unstructured":"Yamada H, Martin P, Suzuki K. Impairment of protein kinase C activity in twitcher Schwann cells in vitro. Brain Res. 1996;718:138\u201344.","journal-title":"Brain Res"},{"key":"1466_CR147","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1194\/jlr.M600084-JLR200","volume":"47","author":"S Giri","year":"2006","unstructured":"Giri S, Khan M, Rattan R, Singh I, Singh AK. Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death. J Lipid Res. 2006;47:1478\u201392.","journal-title":"J Lipid Res"},{"key":"1466_CR148","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/glia.20530","volume":"55","author":"Y Pang","year":"2007","unstructured":"Pang Y, Zheng B, Fan LW, Rhodes PG, Cai Z. IGF-1 protects oligodendrocyte progenitors against TNFalpha-induced damage by activation of PI3K\/Akt and interruption of the mitochondrial apoptotic pathway. Glia. 2007;55:1099\u2013107.","journal-title":"Glia"},{"key":"1466_CR149","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.mcn.2005.08.004","volume":"30","author":"M Zaka","year":"2005","unstructured":"Zaka M, Rafi MA, Rao HZ, Luzi P, Wenger DA. Insulin-like growth factor-1 provides protection against psychosine-induced apoptosis in cultured mouse oligodendrocyte progenitor cells using primarily the PI3K\/Akt pathway. Mol Cell Neurosci. 2005;30:398\u2013407.","journal-title":"Mol Cell Neurosci"},{"key":"1466_CR150","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1523\/JNEUROSCI.0217-13.2013","volume":"33","author":"L Cantuti Castelvetri","year":"2013","unstructured":"Cantuti Castelvetri L, Givogri MI, Hebert A, Smith B, Song Y, Kaminska A, et al. The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3beta and deregulation of molecular motors. J Neurosci. 2013;33:10048\u201356.","journal-title":"J Neurosci"},{"key":"1466_CR151","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1083\/jcb.149.4.943","volume":"149","author":"T Kanazawa","year":"2000","unstructured":"Kanazawa T, Nakamura S, Momoi M, Yamaji T, Takematsu H, Yano H, et al. Inhibition of cytokinesis by a lipid metabolite, psychosine. J Cell Biol. 2000;149:943\u201350.","journal-title":"J Cell Biol"},{"key":"1466_CR152","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12017-010-8133-7","volume":"12","author":"M Eckhardt","year":"2010","unstructured":"Eckhardt M. Pathology and current treatment of neurodegenerative sphingolipidoses. Neuromolecular Med. 2010;12:362\u201382.","journal-title":"Neuromolecular Med"},{"key":"1466_CR153","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1476-511X-10-28","volume":"10","author":"M Blomqvist","year":"2011","unstructured":"Blomqvist M, Gieselmann V, Mansson JE. Accumulation of lysosulfatide in the brain of arylsulfatase A-deficient mice. Lipids Health Dis. 2011;10:28.","journal-title":"Lipids Health Dis"},{"key":"1466_CR154","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1515\/bchm3.1986.367.1.241","volume":"367","author":"S Neuenhofer","year":"1986","unstructured":"Neuenhofer S, Conzelmann E, Schwarzmann G, Egge H, Sandhoff K. Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. Biol Chem Hoppe Seyler. 1986;367:241\u20134.","journal-title":"Biol Chem Hoppe Seyler"},{"key":"1466_CR155","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.nbd.2003.08.016","volume":"14","author":"UH Schueler","year":"2003","unstructured":"Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003;14:595\u2013601.","journal-title":"Neurobiol Dis"},{"key":"1466_CR156","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3346\/jkms.2006.21.4.733","volume":"21","author":"YB Hong","year":"2006","unstructured":"Hong YB, Kim EY, Jung SC. Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J Korean Med Sci. 2006;21:733\u20138.","journal-title":"J Korean Med Sci"},{"key":"1466_CR157","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","volume":"285","author":"EB Vitner","year":"2010","unstructured":"Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem. 2010;285:20423\u20137.","journal-title":"J Biol Chem"},{"key":"1466_CR158","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nm.1876","volume":"14","author":"E Lloyd-Evans","year":"2008","unstructured":"Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Sillence DJ, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med. 2008;14:1247\u201355.","journal-title":"Nat Med"},{"key":"1466_CR159","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E","volume":"58","author":"DF Clayton","year":"1999","unstructured":"Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res. 1999;58:120\u20139.","journal-title":"J Neurosci Res"},{"key":"1466_CR160","doi-asserted-by":"crossref","unstructured":"Navarro-Romero A, Montpeyo M, Martinez-Vicente M. The Emerging Role of the Lysosome in Parkinson's Disease. Cells. 2020;9.","DOI":"10.3390\/cells9112399"},{"key":"1466_CR161","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.neulet.2014.09.041","volume":"583","author":"SN Pchelina","year":"2014","unstructured":"Pchelina SN, Nuzhnyi EP, Emelyanov AK, Boukina TM, Usenko TS, Nikolaev MA, et al. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci Lett. 2014;583:188\u201393.","journal-title":"Neurosci Lett"},{"key":"1466_CR162","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","volume":"23","author":"N Plotegher","year":"2017","unstructured":"Plotegher N, Duchen MR. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders. Trends Mol Med. 2017;23:116\u201334.","journal-title":"Trends Mol Med"},{"key":"1466_CR163","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1242\/jcs.180737","volume":"129","author":"PR Angelova","year":"2016","unstructured":"Angelova PR, Ludtmann MH, Horrocks MH, Negoda A, Cremades N, Klenerman D, et al. Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. J Cell Sci. 2016;129:1792\u2013801.","journal-title":"J Cell Sci"},{"key":"1466_CR164","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4161\/auto.26751","volume":"10","author":"JX Song","year":"2014","unstructured":"Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, et al. HMGB1 is involved in autophagy inhibition caused by SNCA\/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy. 2014;10:144\u201354.","journal-title":"Autophagy"},{"key":"1466_CR165","first-page":"e157","volume":"15","author":"WG Land","year":"2015","unstructured":"Land WG. The Role of Damage-Associated Molecular Patterns (DAMPs) in Human Diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ Med J. 2015;15:e157\u201370.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"1466_CR166","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1172\/JCI34431","volume":"118","author":"GM Barton","year":"2008","unstructured":"Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest. 2008;118:413\u201320.","journal-title":"J Clin Invest"},{"key":"1466_CR167","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122:19\u201327.","journal-title":"Mol Genet Metab"},{"key":"1466_CR168","first-page":"205","volume":"10","author":"V Barak","year":"1999","unstructured":"Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw. 1999;10:205\u201310.","journal-title":"Eur Cytokine Netw"},{"key":"1466_CR169","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM. 1997;90:19\u201325.","journal-title":"QJM"},{"key":"1466_CR170","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ajh.21492","volume":"84","author":"M Machaczka","year":"2009","unstructured":"Machaczka M, Lerner R, Klimkowska M, Hagglund H. Treatment of multiple myeloma in patients with Gaucher disease. Am J Hematol. 2009;84:694\u20136.","journal-title":"Am J Hematol"},{"key":"1466_CR171","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","volume":"122","author":"LA Boven","year":"2004","unstructured":"Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122:359\u201369.","journal-title":"Am J Clin Pathol"},{"key":"1466_CR172","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 1997;23:201\u201312.","journal-title":"Blood Cells Mol Dis"},{"key":"1466_CR173","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","volume":"20","author":"T Farfel-Becker","year":"2011","unstructured":"Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet. 2011;20:1375\u201386.","journal-title":"Hum Mol Genet"},{"key":"1466_CR174","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/brain\/aws095","volume":"135","author":"EB Vitner","year":"2012","unstructured":"Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain. 2012;135:1724\u201335.","journal-title":"Brain"},{"key":"1466_CR175","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3727\/096368916X694265","volume":"26","author":"WL Tseng","year":"2017","unstructured":"Tseng WL, Chou SJ, Chiang HC, Wang ML, Chien CS, Chen KH, et al. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells. Cell Transplant. 2017;26:513\u201327.","journal-title":"Cell Transplant"},{"key":"1466_CR176","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ymgme.2013.01.018","volume":"108","author":"CS Pereira","year":"2013","unstructured":"Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF. Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab. 2013;108:241\u20138.","journal-title":"Mol Genet Metab"},{"key":"1466_CR177","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/emmm.201202301","volume":"5","author":"AM Alayoubi","year":"2013","unstructured":"Alayoubi AM, Wang JC, Au BC, Carpentier S, Garcia V, Dworski S, et al. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med. 2013;5:827\u201342.","journal-title":"EMBO Mol Med"},{"key":"1466_CR178","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ana.20242","volume":"56","author":"M Jeyakumar","year":"2004","unstructured":"Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, Butters TD, et al. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol. 2004;56:642\u20139.","journal-title":"Ann Neurol"},{"key":"1466_CR179","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.nbd.2009.07.010","volume":"36","author":"D Smith","year":"2009","unstructured":"Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis. 2009;36:242\u201351.","journal-title":"Neurobiol Dis"},{"key":"1466_CR180","doi-asserted-by":"publisher","first-page":"21673","DOI":"10.1074\/jbc.274.31.21673","volume":"274","author":"E Korkotian","year":"1999","unstructured":"Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem. 1999;274:21673\u20138.","journal-title":"J Biol Chem"},{"key":"1466_CR181","doi-asserted-by":"publisher","first-page":"23594","DOI":"10.1074\/jbc.M300212200","volume":"278","author":"E Lloyd-Evans","year":"2003","unstructured":"Lloyd-Evans E, Pelled D, Riebeling C, Bodennec J, de-Morgan, A., Waller, H., Schiffmann, R., and Futerman, A. H. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem. 2003;278:23594\u20139.","journal-title":"J Biol Chem"},{"key":"1466_CR182","doi-asserted-by":"publisher","first-page":"29496","DOI":"10.1074\/jbc.M302964200","volume":"278","author":"D Pelled","year":"2003","unstructured":"Pelled D, Lloyd-Evans E, Riebeling C, Jeyakumar M, Platt FM, Futerman AH. Inhibition of calcium uptake via the sarco\/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J Biol Chem. 2003;278:29496\u2013501.","journal-title":"J Biol Chem"},{"key":"1466_CR183","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/j.1471-4159.2005.03534.x","volume":"95","author":"L Ginzburg","year":"2005","unstructured":"Ginzburg L, Futerman AH. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J Neurochem. 2005;95:1619\u201328.","journal-title":"J Neurochem"},{"key":"1466_CR184","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1471-4159.2007.04983.x","volume":"104","author":"L Ginzburg","year":"2008","unstructured":"Ginzburg L, Li SC, Li YT, Futerman AH. An exposed carboxyl group on sialic acid is essential for gangliosides to inhibit calcium uptake via the sarco\/endoplasmic reticulum Ca2+-ATPase: relevance to gangliosidoses. J Neurochem. 2008;104:140\u20136.","journal-title":"J Neurochem"},{"key":"1466_CR185","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.molcel.2009.10.021","volume":"36","author":"R Sano","year":"2009","unstructured":"Sano R, Annunziata I, Patterson A, Moshiach S, Gomero E, Opferman J, et al. GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca (2+)-dependent mitochondrial apoptosis. Mol Cell. 2009;36:500\u201311.","journal-title":"Mol Cell"},{"key":"1466_CR186","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.abb.2004.04.009","volume":"427","author":"Y Zhao","year":"2004","unstructured":"Zhao Y, Fan X, Yang F, Zhang X. Gangliosides modulate the activity of the plasma membrane Ca (2+)-ATPase from porcine brain synaptosomes. Arch Biochem Biophys. 2004;427:204\u201312.","journal-title":"Arch Biochem Biophys"},{"key":"1466_CR187","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.febslet.2005.03.038","volume":"579","author":"Y Pang","year":"2005","unstructured":"Pang Y, Zhu H, Wu P, Chen J. The characterization of plasma membrane Ca2+-ATPase in rich sphingomyelin-cholesterol domains. FEBS Lett. 2005;579:2397\u2013403.","journal-title":"FEBS Lett"},{"key":"1466_CR188","doi-asserted-by":"publisher","first-page":"e1529","DOI":"10.1038\/cddis.2014.483","volume":"5","author":"V Voccoli","year":"2014","unstructured":"Voccoli V, Tonazzini I, Signore G, Caleo M, Cecchini M. Role of extracellular calcium and mitochondrial oxygen species in psychosine-induced oligodendrocyte cell death. Cell Death Dis. 2014;5:e1529.","journal-title":"Cell Death Dis"},{"key":"1466_CR189","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1042\/BST0381424","volume":"38","author":"A Galione","year":"2010","unstructured":"Galione A, Morgan AJ, Arredouani A, Davis LC, Rietdorf K, Ruas M, et al. NAADP as an intracellular messenger regulating lysosomal calcium-release channels. Biochem Soc Trans. 2010;38:1424\u201331.","journal-title":"Biochem Soc Trans"},{"key":"1466_CR190","doi-asserted-by":"crossref","unstructured":"Li RJ, Xu J, Fu C, Zhang J, Zheng YG, Jia H, et al. Regulation of mTORC1 by lysosomal calcium and calmodulin. Elife. 2016;5.","DOI":"10.7554\/eLife.19360"},{"key":"1466_CR191","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/ncb3114","volume":"17","author":"DL Medina","year":"2015","unstructured":"Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol. 2015;17:288\u201399.","journal-title":"Nat Cell Biol"},{"key":"1466_CR192","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/emboj.2012.32","volume":"31","author":"C Settembre","year":"2012","unstructured":"Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31:1095\u2013108.","journal-title":"EMBO J"},{"key":"1466_CR193","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1016\/j.jmb.2020.02.033","volume":"432","author":"F Darios","year":"2020","unstructured":"Darios F, Stevanin G. Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases. J Mol Biol. 2020;432:2714\u201334.","journal-title":"J Mol Biol"},{"key":"1466_CR194","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1042\/EBC20170055","volume":"61","author":"E Seranova","year":"2017","unstructured":"Seranova E, Connolly KJ, Zatyka M, Rosenstock TR, Barrett T, Tuxworth RI, et al. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem. 2017;61:733\u201349.","journal-title":"Essays Biochem"},{"key":"1466_CR195","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/hmg\/ddm289","volume":"17","author":"C Settembre","year":"2008","unstructured":"Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C, Medina D, et al. A block of autophagy in lysosomal storage disorders. Hum Mol Genet. 2008;17:119\u201329.","journal-title":"Hum Mol Genet"},{"key":"1466_CR196","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbrc.2007.12.187","volume":"367","author":"A Takamura","year":"2008","unstructured":"Takamura A, Higaki K, Kajimaki K, Otsuka S, Ninomiya H, Matsuda J, et al. Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochem Biophys Res Commun. 2008;367:616\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"1466_CR197","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.molcel.2008.06.001","volume":"30","author":"Y Wei","year":"2008","unstructured":"Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008;30:678\u201388.","journal-title":"Mol Cell"},{"key":"1466_CR198","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4161\/auto.19469","volume":"8","author":"AP Lieberman","year":"2012","unstructured":"Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A. Autophagy in lysosomal storage disorders. Autophagy. 2012;8:719\u201330.","journal-title":"Autophagy"},{"key":"1466_CR199","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.4161\/cc.8.13.8892","volume":"8","author":"T Lamark","year":"2009","unstructured":"Lamark T, Kirkin V, Dikic I, Johansen T. NBR1 and p62 as cargo receptors for selective autophagy of ubiquitinated targets. Cell Cycle. 2009;8:1986\u201390.","journal-title":"Cell Cycle"},{"key":"1466_CR200","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1093\/hmg\/ddu105","volume":"23","author":"YH Xu","year":"2014","unstructured":"Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet. 2014;23:3943\u201357.","journal-title":"Hum Mol Genet"},{"key":"1466_CR201","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/hmg\/ddt468","volume":"23","author":"T Farfel-Becker","year":"2014","unstructured":"Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum Mol Genet. 2014;23:843\u201354.","journal-title":"Hum Mol Genet"},{"key":"1466_CR202","doi-asserted-by":"publisher","first-page":"11654","DOI":"10.1523\/JNEUROSCI.4527-15.2016","volume":"36","author":"KJ Kinghorn","year":"2016","unstructured":"Kinghorn KJ, Gr\u00f6nke S, Castillo-Quan JI, Woodling NS, Li L, Sirka E, et al. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin. J Neurosci. 2016;36:11654\u201370.","journal-title":"J Neurosci"},{"key":"1466_CR203","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/nyas.12966","volume":"1371","author":"A Serrano-Puebla","year":"2016","unstructured":"Serrano-Puebla A, Boya P. Lysosomal membrane permeabilization in cell death: new evidence and implications for health and disease. Ann N Y Acad Sci. 2016;1371:30\u201344.","journal-title":"Ann N Y Acad Sci"},{"key":"1466_CR204","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/15216540600904885","volume":"58","author":"A Terman","year":"2006","unstructured":"Terman A, Kurz T, Gustafsson B, Brunk UT. Lysosomal labilization. IUBMB Life. 2006;58:531\u20139.","journal-title":"IUBMB Life"},{"key":"1466_CR205","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbrc.2010.02.087","volume":"393","author":"S Sahara","year":"2010","unstructured":"Sahara S, Yamashima T. Calpain-mediated Hsp70.1 cleavage in hippocampal CA1 neuronal death. Biochem Biophys Res Commun. 2010;393:806\u201311.","journal-title":"Biochem Biophys Res Commun"},{"key":"1466_CR206","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/cdd.2014.4","volume":"21","author":"E Gabande-Rodriguez","year":"2014","unstructured":"Gabande-Rodriguez E, Boya P, Labrador V, Dotti CG, Ledesma MD. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. Cell Death Differ. 2014;21:864\u201375.","journal-title":"Cell Death Differ"},{"key":"1466_CR207","first-page":"174","volume":"11","author":"M Yamane","year":"2017","unstructured":"Yamane M, Moriya S, Kokuba H. Visualization of ceramide channels in lysosomes following endogenous palmitoyl-ceramide accumulation as an initial step in the induction of necrosis. Biochem Biophys Rep. 2017;11:174\u201381.","journal-title":"Biochem Biophys Rep"},{"key":"1466_CR208","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.bbamem.2011.01.007","volume":"1808","author":"S Samanta","year":"2011","unstructured":"Samanta S, Stiban J, Maugel TK, Colombini M. Visualization of ceramide channels by transmission electron microscopy. Biochim Biophys Acta. 2011;1808:1196\u2013201.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR209","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s10495-006-5882-8","volume":"11","author":"J Stiban","year":"2006","unstructured":"Stiban J, Fistere D, Colombini M. Dihydroceramide hinders ceramide channel formation: Implications on apoptosis. Apoptosis. 2006;11:773\u201380.","journal-title":"Apoptosis"},{"key":"1466_CR210","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/febs.13190","volume":"282","author":"M Doerflinger","year":"2015","unstructured":"Doerflinger M, Glab JA, Puthalakath H. BH3-only proteins: a 20-year stock-take. FEBS J. 2015;282:1006\u201316.","journal-title":"FEBS J"},{"key":"1466_CR211","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.freeradbiomed.2013.05.051","volume":"65","author":"CO Eno","year":"2013","unstructured":"Eno CO, Zhao G, Venkatanarayan A, Wang B, Flores ER, Li C. Noxa couples lysosomal membrane permeabilization and apoptosis during oxidative stress. Free Radic Biol Med. 2013;65:26\u201337.","journal-title":"Free Radic Biol Med"},{"key":"1466_CR212","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/82732","volume":"1","author":"N Holler","year":"2000","unstructured":"Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489\u201395.","journal-title":"Nat Immunol"},{"key":"1466_CR213","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1093\/hmg\/ddq273","volume":"19","author":"EB Vitner","year":"2010","unstructured":"Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R, et al. Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses. Hum Mol Genet. 2010;19:3583\u201390.","journal-title":"Hum Mol Genet"},{"key":"1466_CR214","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nm.3449","volume":"20","author":"EB Vitner","year":"2014","unstructured":"Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med. 2014;20:204\u20138.","journal-title":"Nat Med"},{"key":"1466_CR215","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s10038-018-0445-8","volume":"63","author":"K Irahara-Miyana","year":"2018","unstructured":"Irahara-Miyana K, Otomo T, Kondo H, Hossain MA, Ozono K, Sakai N. Unfolded protein response is activated in Krabbe disease in a manner dependent on the mutation type. J Hum Genet. 2018;63:699\u2013706.","journal-title":"J Hum Genet"},{"key":"1466_CR216","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molcel.2004.08.029","volume":"15","author":"A Tessitore","year":"2004","unstructured":"Tessitore A, del Martin MP, Sano R, Ma Y, Mann L, Ingrassia A, et al. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell. 2004;15:753\u201366.","journal-title":"Mol Cell"},{"key":"1466_CR217","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/hmg\/ddm324","volume":"17","author":"H Wei","year":"2008","unstructured":"Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet. 2008;17:469\u201377.","journal-title":"Hum Mol Genet"},{"key":"1466_CR218","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0140-6736(98)10034-X","volume":"354","author":"CS Chen","year":"1999","unstructured":"Chen CS, Patterson MC, Wheatley CL, O'Brien JF, Pagano RE. Broad screening test for sphingolipid-storage diseases. Lancet. 1999;354:901\u20135.","journal-title":"Lancet"},{"key":"1466_CR219","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1194\/jlr.M200232-JLR200","volume":"43","author":"DJ Sillence","year":"2002","unstructured":"Sillence DJ, Puri V, Marks DL, Butters TD, Dwek RA, Pagano RE, et al. Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res. 2002;43:1837\u201345.","journal-title":"J Lipid Res"},{"key":"1466_CR220","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/sj.gt.3302834","volume":"13","author":"D Klein","year":"2006","unstructured":"Klein D, Schmandt T, Muth-Kohne E, Perez-Bouza A, Segschneider M, Gieselmann V, et al. Embryonic stem cell-based reduction of central nervous system sulfatide storage in an animal model of metachromatic leukodystrophy. Gene Ther. 2006;13:1686\u201395.","journal-title":"Gene Ther"},{"key":"1466_CR221","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/10084","volume":"1","author":"T Kobayashi","year":"1999","unstructured":"Kobayashi T, Beuchat MH, Lindsay M, Frias S, Palmiter RD, Sakuraba H, et al. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nat Cell Biol. 1999;1:113\u20138.","journal-title":"Nat Cell Biol"},{"key":"1466_CR222","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1021\/acs.molpharmaceut.5b00542","volume":"13","author":"J Rappaport","year":"2016","unstructured":"Rappaport J, Manthe RL, Solomon M, Garnacho C, Muro S. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Mol Pharm. 2016;13:357\u201368.","journal-title":"Mol Pharm"},{"key":"1466_CR223","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/emboj.2010.237","volume":"29","author":"A Fraldi","year":"2010","unstructured":"Fraldi A, Annunziata F, Lombardi A, Kaiser HJ, Medina DL, Spampanato C, et al. Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J. 2010;29:3607\u201320.","journal-title":"EMBO J"},{"key":"1466_CR224","doi-asserted-by":"publisher","first-page":"15294","DOI":"10.1073\/pnas.261560998","volume":"98","author":"A Almeida","year":"2001","unstructured":"Almeida A, Almeida J, Bolanos JP, Moncada S. Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A. 2001;98:15294\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1466_CR225","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","volume":"17","author":"LD Osellame","year":"2013","unstructured":"Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson's disease. Cell Metab. 2013;17:941\u201353.","journal-title":"Cell Metab"},{"key":"1466_CR226","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/mmi.12470","volume":"91","author":"R Vilaca","year":"2014","unstructured":"Vilaca R, Silva E, Nadais A, Teixeira V, Matmati N, Gaifem J, et al. Sphingolipid signalling mediates mitochondrial dysfunctions and reduced chronological lifespan in the yeast model of Niemann-Pick type C1. Mol Microbiol. 2014;91:438\u201351.","journal-title":"Mol Microbiol"},{"key":"1466_CR227","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1460-9568.2010.07345.x","volume":"32","author":"AF MacAskill","year":"2010","unstructured":"MacAskill AF, Atkin TA, Kittler JT. Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses. Eur J Neurosci. 2010;32:231\u201340.","journal-title":"Eur J Neurosci"},{"key":"1466_CR228","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.200809125","volume":"183","author":"D Narendra","year":"2008","unstructured":"Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183:795\u2013803.","journal-title":"J Cell Biol"},{"key":"1466_CR229","doi-asserted-by":"crossref","unstructured":"Barazzuol L, Giamogante F, Brini M, Cali T. PINK1\/Parkin Mediated Mitophagy, Ca (2+) Signalling, and ER-Mitochondria Contacts in Parkinson's Disease. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21051772"},{"key":"1466_CR230","doi-asserted-by":"publisher","first-page":"e0165780","DOI":"10.1371\/journal.pone.0165780","volume":"11","author":"B Canonico","year":"2016","unstructured":"Canonico B, Cesarini E, Salucci S, Luchetti F, Falcieri E, Di Sario G, et al. Defective Autophagy, Mitochondrial Clearance and Lipophagy in Niemann-Pick Type B Lymphocytes. PLoS One. 2016;11:e0165780.","journal-title":"PLoS One"},{"key":"1466_CR231","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcp.21023","volume":"212","author":"M Deganuto","year":"2007","unstructured":"Deganuto M, Pittis MG, Pines A, Dominissini S, Kelley MR, Garcia R, et al. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol. 2007;212:223\u201335.","journal-title":"J Cell Physiol"},{"key":"1466_CR232","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/brain\/awg089","volume":"126","author":"M Jeyakumar","year":"2003","unstructured":"Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003;126:974\u201387.","journal-title":"Brain"},{"key":"1466_CR233","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1111\/j.1582-4934.2008.00493.x","volume":"13","author":"S Zampieri","year":"2009","unstructured":"Zampieri S, Mellon SH, Butters TD, Nevyjel M, Covey DF, Bembi B, et al. Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J Cell Mol Med. 2009;13:3786\u201396.","journal-title":"J Cell Mol Med"},{"key":"1466_CR234","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.expneurol.2016.07.011","volume":"284","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamaguchi A, Yamanaka S, Kanzaki S, Kawashima M, Togo T, et al. Accumulated alpha-synuclein affects the progression of GM2 gangliosidoses. Exp Neurol. 2016;284:38\u201349.","journal-title":"Exp Neurol"},{"key":"1466_CR235","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.bbamem.2014.11.018","volume":"1848","author":"J Stiban","year":"2015","unstructured":"Stiban J, Perera M. Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis. Biochim Biophys Acta. 2015;1848:561\u20137.","journal-title":"Biochim Biophys Acta"},{"key":"1466_CR236","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-030-21162-2_3","volume":"1159","author":"M Colombini","year":"2019","unstructured":"Colombini M. Ceramide Channels. Adv Exp Med Biol. 2019;1159:33\u201348.","journal-title":"Adv Exp Med Biol"},{"key":"1466_CR237","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10863-016-9646-z","volume":"49","author":"M Colombini","year":"2017","unstructured":"Colombini M. Ceramide channels and mitochondrial outer membrane permeability. J Bioenerg Biomembr. 2017;49:57\u201364.","journal-title":"J Bioenerg Biomembr"},{"key":"1466_CR238","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1042\/BJ20112103","volume":"445","author":"MN Perera","year":"2012","unstructured":"Perera MN, Lin SH, Peterson YK, Bielawska A, Szulc ZM, Bittman R, et al. Bax and Bcl-xL exert their regulation on different sites of the ceramide channel. Biochem J. 2012;445:81\u201391.","journal-title":"Biochem J"},{"key":"1466_CR239","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1194\/jlr.R003996","volume":"51","author":"YH Xu","year":"2010","unstructured":"Xu YH, Barnes S, Sun Y, Grabowski GA. Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res. 2010;51:1643\u201375.","journal-title":"J Lipid Res"},{"key":"1466_CR240","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/B978-0-444-59565-2.00055-1","volume":"113","author":"V Valayannopoulos","year":"2013","unstructured":"Valayannopoulos V. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression. Handb Clin Neurol. 2013;113:1851\u20137.","journal-title":"Handb Clin Neurol"},{"key":"1466_CR241","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dmcn.13600","volume":"60","author":"M Beck","year":"2018","unstructured":"Beck M. Treatment strategies for lysosomal storage disorders. Dev Med Child Neurol. 2018;60:13\u20138.","journal-title":"Dev Med Child Neurol"},{"key":"1466_CR242","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13023-014-0112-x","volume":"9","author":"L van Dussen","year":"2014","unstructured":"van Dussen L, Biegstraaten M, Dijkgraaf MG, Hollak CE. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis. 2014;9:112.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR243","doi-asserted-by":"publisher","first-page":"102735","DOI":"10.1016\/j.ebiom.2020.102735","volume":"55","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liou B, Chu Z, Fannin V, Blackwood R, Peng Y, et al. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine. 2020;55:102735.","journal-title":"EBioMedicine"},{"key":"1466_CR244","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","volume":"118","author":"M Solomon","year":"2017","unstructured":"Solomon M, Muro S. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017;118:109\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"1466_CR245","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/hmg\/ddz020","volume":"28","author":"H Simonis","year":"2019","unstructured":"Simonis H, Yaghootfam C, Sylvester M, Gieselmann V, Matzner U. Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy. Hum Mol Genet. 2019;28:1810\u201321.","journal-title":"Hum Mol Genet"},{"key":"1466_CR246","doi-asserted-by":"publisher","first-page":"e0195186","DOI":"10.1371\/journal.pone.0195186","volume":"13","author":"T Wright","year":"2018","unstructured":"Wright T, Li A, Lotterhand J, Graham AR, Huang Y, Avila N, et al. Nonclinical comparability studies of recombinant human arylsulfatase A addressing manufacturing process changes. PLoS One. 2018;13:e0195186.","journal-title":"PLoS One"},{"key":"1466_CR247","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"1466_CR248","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"1466_CR249","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21:345\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"1466_CR250","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524\u20139.","journal-title":"Circulation"},{"key":"1466_CR251","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"1466_CR252","doi-asserted-by":"crossref","unstructured":"Hamidieh AA, Rostami T, Behfar M, Kiumarsi A, Ghavamzadeh A. Favorable outcome of allogenic hematopoietic stem cell transplantation in farber disease. Inl J Clin Rheumatol. 2018;13.","DOI":"10.4172\/1758-4272.1000204"},{"key":"1466_CR253","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","volume":"18","author":"AI Guce","year":"2011","unstructured":"Guce AI, Clark NE, Rogich JJ, Garman SC. The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol. 2011;18:1521\u20136.","journal-title":"Chem Biol"},{"key":"1466_CR254","doi-asserted-by":"publisher","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","volume":"290","author":"GH Yam","year":"2006","unstructured":"Yam GH, Bosshard N, Zuber C, Steinmann B, Roth J. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol. 2006;290:C1076\u201382.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1466_CR255","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/mt.2009.220","volume":"18","author":"R Khanna","year":"2010","unstructured":"Khanna R, Soska R, Lun Y, Feng J, Frascella M, Young B, et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther. 2010;18:23\u201333.","journal-title":"Mol Ther"},{"key":"1466_CR256","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1021\/jm301557k","volume":"56","author":"RE Boyd","year":"2013","unstructured":"Boyd RE, Lee G, Rybczynski P, Benjamin ER, Khanna R, Wustman BA, et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem. 2013;56:2705\u201325.","journal-title":"J Med Chem"},{"key":"1466_CR257","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/adt.2011.0370","volume":"9","author":"KJ Valenzano","year":"2011","unstructured":"Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, Flanagan JJ, et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol. 2011;9:213\u201335.","journal-title":"Assay Drug Dev Technol"},{"key":"1466_CR258","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nchembio850","volume":"3","author":"RL Lieberman","year":"2007","unstructured":"Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, Khanna R, et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2007;3:101\u20137.","journal-title":"Nat Chem Biol"},{"key":"1466_CR259","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","volume":"287","author":"Y Sun","year":"2012","unstructured":"Sun Y, Liou B, Xu YH, Quinn B, Zhang W, Hamler R, et al. Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem. 2012;287:4275\u201387.","journal-title":"J Biol Chem"},{"key":"1466_CR260","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GH Maegawa","year":"2009","unstructured":"Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284:23502\u201316.","journal-title":"J Biol Chem"},{"key":"1466_CR261","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bcmd.2013.03.006","volume":"51","author":"A Sanders","year":"2013","unstructured":"Sanders A, Hemmelgarn H, Melrose HL, Hein L, Fuller M, Clarke LA. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease. Blood Cells Mol Dis. 2013;51:109\u201315.","journal-title":"Blood Cells Mol Dis"},{"key":"1466_CR262","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymgme.2012.02.012","volume":"106","author":"Y Suzuki","year":"2012","unstructured":"Suzuki Y, Ichinomiya S, Kurosawa M, Matsuda J, Ogawa S, Iida M, et al. Therapeutic chaperone effect of N-octyl 4-epi-beta-valienamine on murine G(M1)-gangliosidosis. Mol Genet Metab. 2012;106:92\u20138.","journal-title":"Mol Genet Metab"},{"key":"1466_CR263","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. Mol Ther. 2015;23:1138\u201348.","journal-title":"Mol Ther"},{"key":"1466_CR264","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s13311-011-0067-8","volume":"8","author":"LS Shihabuddin","year":"2011","unstructured":"Shihabuddin LS, Cheng SH. Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases. Neurotherapeutics. 2011;8:659\u201367.","journal-title":"Neurotherapeutics"},{"key":"1466_CR265","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13023-019-1220-4","volume":"14","author":"S Beerepoot","year":"2019","unstructured":"Beerepoot S, Nierkens S, Boelens JJ, Lindemans C, Bugiani M, Wolf NI. Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Orphanet J Rare Dis. 2019;14:240.","journal-title":"Orphanet J Rare Dis"},{"key":"1466_CR266","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa042604","volume":"352","author":"ML Escolar","year":"2005","unstructured":"Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005;352:2069\u201381.","journal-title":"N Engl J Med"},{"key":"1466_CR267","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bmt.1702489","volume":"26","author":"AM Yeager","year":"2000","unstructured":"Yeager AM, Uhas KA, Coles CD, Davis PC, Krause WL, Moser HW. Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant. 2000;26:357\u201363.","journal-title":"Bone Marrow Transplant"},{"key":"1466_CR268","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.seminhematol.2009.10.006","volume":"47","author":"PJ Orchard","year":"2010","unstructured":"Orchard PJ, Tolar J. Transplant outcomes in leukodystrophies. Semin Hematol. 2010;47:70\u20138.","journal-title":"Semin Hematol"},{"key":"1466_CR269","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nm0496-424","volume":"2","author":"HD Lacorazza","year":"1996","unstructured":"Lacorazza HD, Flax JD, Snyder EY, Jendoubi M. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med. 1996;2:424\u20139.","journal-title":"Nat Med"},{"key":"1466_CR270","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nm1548","volume":"13","author":"JP Lee","year":"2007","unstructured":"Lee JP, Jeyakumar M, Gonzalez R, Takahashi H, Lee PJ, Baek RC, et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med. 2007;13:439\u201347.","journal-title":"Nat Med"},{"key":"1466_CR271","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.brainres.2007.01.011","volume":"1140","author":"RL Sidman","year":"2007","unstructured":"Sidman RL, Li J, Stewart GR, Clarke J, Yang W, Snyder EY, et al. Injection of mouse and human neural stem cells into neonatal Niemann-Pick A model mice. Brain Res. 2007;1140:195\u2013204.","journal-title":"Brain Res"},{"key":"1466_CR272","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1292\/jvms.09-0514","volume":"72","author":"JM Lee","year":"2010","unstructured":"Lee JM, Bae JS, Jin HK. Intracerebellar transplantation of neural stem cells into mice with neurodegeneration improves neuronal networks with functional synaptic transmission. J Vet Med Sci. 2010;72:999\u20131009.","journal-title":"J Vet Med Sci"},{"key":"1466_CR273","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neulet.2005.02.029","volume":"381","author":"JS Bae","year":"2005","unstructured":"Bae JS, Furuya S, Ahn SJ, Yi SJ, Hirabayashi Y, Jin HK. Neuroglial activation in Niemann-Pick Type C mice is suppressed by intracerebral transplantation of bone marrow-derived mesenchymal stem cells. Neurosci Lett. 2005;381:234\u20136.","journal-title":"Neurosci Lett"},{"key":"1466_CR274","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/scrt125","volume":"3","author":"HP Huang","year":"2012","unstructured":"Huang HP, Chuang CY, Kuo HC. Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases. Stem Cell Res Ther. 2012;3:34.","journal-title":"Stem Cell Res Ther"},{"key":"1466_CR275","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","volume":"13","author":"MS Sands","year":"2006","unstructured":"Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther. 2006;13:839\u201349.","journal-title":"Mol Ther"},{"key":"1466_CR276","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.","journal-title":"Science"},{"key":"1466_CR277","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/hum.2012.052","volume":"23","author":"EA Salegio","year":"2012","unstructured":"Salegio EA, Samaranch L, Jenkins RW, Clarke CJ, Lamarre C, Beyer J, et al. Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther. 2012;23:891\u2013902.","journal-title":"Hum Gene Ther"},{"key":"1466_CR278","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/hum.2018.072","volume":"30","author":"S Du","year":"2019","unstructured":"Du S, Ou H, Cui R, Jiang N, Zhang M, Li X, et al. Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy as a Treatment Strategy in Mouse Models of Gaucher Disease. Hum Gene Ther. 2019;30:155\u201367.","journal-title":"Hum Gene Ther"},{"key":"1466_CR279","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1194\/jlr.M071274","volume":"58","author":"C Xie","year":"2017","unstructured":"Xie C, Gong XM, Luo J, Li BL, Song BL. AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease. J Lipid Res. 2017;58:512\u20138.","journal-title":"J Lipid Res"},{"key":"1466_CR280","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddy212","volume":"27","author":"MP Hughes","year":"2018","unstructured":"Hughes MP, Smith DA, Morris L, Fletcher C, Colaco A, Huebecker M, et al. AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease. Hum Mol Genet. 2018;27:3079\u201398.","journal-title":"Hum Mol Genet"},{"key":"1466_CR281","doi-asserted-by":"crossref","unstructured":"Chang, S.-K., Lu, Y.-H., Chen, Y.-R., Hsieh, Y.-P., Lin, W.-J., Hsu, T.-R., and Niu, D.-M. (2017) AB043. Correction of the GLA IVS4+919 G>A mutation with CRISPR\/Cas9 deletion strategy in fibroblasts of Fabry disease. Annals of Translational Medicine, 41","DOI":"10.21037\/atm.2017.s043"},{"key":"1466_CR282","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1194\/jlr.M081323","volume":"59","author":"ML Allende","year":"2018","unstructured":"Allende ML, Cook EK, Larman BC, Nugent A, Brady JM, Golebiowski D, et al. Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation. J Lipid Res. 2018;59:550\u201363.","journal-title":"J Lipid Res"},{"key":"1466_CR283","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.isci.2019.04.036","volume":"15","author":"DP Dever","year":"2019","unstructured":"Dever DP, Scharenberg SG, Camarena J, Kildebeck EJ, Clark JT, Martin RM, et al. CRISPR\/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells. iScience. 2019;15:524\u201335.","journal-title":"iScience"},{"key":"1466_CR284","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1310\/hpj5107-553","volume":"51","author":"A Van Rossum","year":"2016","unstructured":"Van Rossum A, Holsopple M. Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options. Hosp Pharm. 2016;51:553\u201363.","journal-title":"Hosp Pharm"},{"key":"1466_CR285","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1172\/JCI5542","volume":"103","author":"Y Liu","year":"1999","unstructured":"Liu Y, Wada R, Kawai H, Sango K, Deng C, Tai T, et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest. 1999;103:497\u2013505.","journal-title":"J Clin Invest"},{"key":"1466_CR286","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481\u20135.","journal-title":"Lancet"},{"key":"1466_CR287","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","volume":"35","author":"P Alfonso","year":"2005","unstructured":"Alfonso P, Pampin S, Estrada J, Rodriguez-Rey JC, Giraldo P, Sancho J, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis. 2005;35:268\u201376.","journal-title":"Blood Cells Mol Dis"},{"key":"1466_CR288","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1021\/mp200313e","volume":"8","author":"O Abian","year":"2011","unstructured":"Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm. 2011;8:2390\u20137.","journal-title":"Mol Pharm"},{"key":"1466_CR289","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.nbd.2004.04.012","volume":"16","author":"U Andersson","year":"2004","unstructured":"Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, et al. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis. 2004;16:506\u201315.","journal-title":"Neurobiol Dis"},{"key":"1466_CR290","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajh.25300","volume":"94","author":"E Lukina","year":"2019","unstructured":"Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. Am J Hematol. 2019;94:29\u201338.","journal-title":"Am J Hematol"},{"key":"1466_CR291","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, et al. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease. Mol Med. 2015;21:389\u201399.","journal-title":"Mol Med"},{"key":"1466_CR292","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1097-4547(20000415)60:2<231::AID-JNR12>3.0.CO;2-E","volume":"60","author":"SM LeVine","year":"2000","unstructured":"LeVine SM, Pedchenko TV, Bronshteyn IG, Pinson DM. L-cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice). J Neurosci Res. 2000;60:231\u20136.","journal-title":"J Neurosci Res"},{"key":"1466_CR293","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765\u201372.","journal-title":"Lancet Neurol"},{"key":"1466_CR294","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/S0140-6736(17)31465-4","volume":"390","author":"DS Ory","year":"2017","unstructured":"Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet. 2017;390:1758\u201368.","journal-title":"Lancet"},{"key":"1466_CR295","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/hmg\/ddy112","volume":"27","author":"A Cougnoux","year":"2018","unstructured":"Cougnoux A, Drummond RA, Collar AL, Iben JR, Salman A, Westgarth H, et al. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention. Hum Mol Genet. 2018;27:2076\u201389.","journal-title":"Hum Mol Genet"},{"key":"1466_CR296","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S0140-6736(17)31631-8","volume":"390","author":"RP Erickson","year":"2017","unstructured":"Erickson RP, Fiorenza MT. A hopeful therapy for Niemann-Pick C diseases. Lancet. 2017;390:1720\u20131.","journal-title":"Lancet"},{"key":"1466_CR297","doi-asserted-by":"crossref","unstructured":"Fukaura, M., Ishitsuka, Y., Shirakawa, S., Ushihama, N., Yamada, Y., Kondo, Y., Takeo, T., Nakagata, N., Motoyama, K., Higashi, T., Arima, H., Kurauchi, Y., Seki, T., Katsuki, H., Higaki, K., Matsuo, M., and Irie, T. (2021) Intracerebroventricular Treatment with 2-Hydroxypropyl-beta-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice. Int J Mol Sci 22","DOI":"10.3390\/ijms22010452"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01466-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T22:37:34Z","timestamp":1724971054000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":297,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01466-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"44"}}